Sapacitabine

CAS : 151823-14-2

Ref. 3D-NS29828

Informations sur le produit

• Nom: Sapacitabine
• Synonymes: 1-(2-Deoxy-2-cyano-b-D-arabinofuranosyl)cytosine, 1-(2-cyano-2-deoxy-beta-D-arabinofuranosyl)-4-(hexadecanoylamino)pyrimidin-2(1H)-one, Cs-682, Cyc 682, Hexadecanamide, N-[1-(2-cyano-2-deoxy-β-<span class="text-smallcaps">D</span>-arabinofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]-, N-[1-(2-Cyano-2-deoxy-β-<span class="text-smallcaps">D</span>-arabinofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]hexadecanamide, N-[1-[(2R,3S,4S,5R)-3-cyano-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2- oxo-pyrimidin-4-yl]hexadecanamide

Description

Sapacitabine is an oral prodrug that is converted to its active form, the cytotoxic agent 9-β-D-arabinofuranosyladenine (araA), by cellular enzymes. It has potent antitumor activity against solid tumours and has been shown to be effective in a variety of human cancer cell lines. Sapacitabine targets intracellular targets, including DNA methyltransferases and other enzymes involved in the synthesis of RNA and DNA. The drug has been shown to have synergistic effects when used with other cytotoxic agents such as 5-fluorouracil and gemcitabine, which are also inhibitors of DNA methyltransferase.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 490.64 g/mol
• Formule: C₂₆H₄₂N₄O₅
• Degré de pureté: Min. 95%